MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma Review

  

Authors:	Ryan, C. E.; Davids, M. S.; Hermann, R.; Shahkarami, M.; Biondo, J.; Abhyankar, S.; Alhasani, H.; Sharman, J. P.; Mato, A. R.; Roeker, L. E.
Review Title:	MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Journal Title:	Future Oncology
Volume:	18
Issue:	33
ISSN:	1479-6694
Publisher:	Future Medicine
Date Published:	2022-10-01
Start Page:	3689
End Page:	3699
Language:	English
DOI:	10.2217/fon-2022-0456
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PUBMED:	36102212
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=160929535&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Erratum to be found at DOI: 10.2217/fon-2022-0456c1 -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/202119